News

The new drug application (NDA) will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009. According to

Innovent Oncology offers payers and oncologists solutions that combine evidence-based treatment guidelines, patient support services and advance care planning to improve clinical outcomes while addressing costs, the company

This clearance enables the initiation of the clinical trial addressing this significant target at the medical center within a month. The intended product, primarily for the oncology market,

Oritavancin is Targanta’s lead antibiotic candidate targeting gram-positive organisms, including methicillin-resistant Staphylococcus aureus, or MRSA. Oritavancin, administered in a single or in an infrequent dosing regimen, demonstrated comparable

Fahar Merchant, president and CEO of Protox, said: “Protox is very pleased to have completed this clinical trial ahead of schedule and looks forward to releasing top line

Chromatin immunoprecipitation (ChIP) is a technique that helps researchers understand the relationship between DNA and the proteins that impact gene regulation. The collaboration is expected to combine Millipore’s

The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk’s internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund,

Dosing has been completed in the first cohort of healthy volunteer subjects in the single ascending dose, double-blind, placebo-controlled trial, which will enroll approximately 30 subjects. This study

According to the news source, drug majors are increasingly looking towards the academia to overcome limited late-stage pipelines and failures in drug development. Rise in generic competition for